Trial Profile
A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms JACCRO CC-16; JACCRO CC-16AR
- 21 Jan 2023 Results (n=41) assessing associations between AFs and RAS status presented at the 2023 Gastrointestinal Cancers Symposium
- 18 Nov 2018 New trial record